through conference calls if necessary or
ACCELERATEûPRICINGûINûSOMEûCASES
AQUESTIVE THERAPEUTICS and its advisors
made the deliberate decision at the
OUTSETûOFûMARKETINGûITSû)0/ûTOûDROPûTHEû
swing day from its roadshow schedule,
rather than get caught up in the swarm
of new issues that priced on Wednesday
NIGHT
The result was a midpoint outcome on a
53MûRAISEûTHATûWASûUPSIZEDûANDûTRADEDû
UPûINûTHEûAFTERMARKET
BMO Capital Markets and RBC Capital Markets
PRICEDûMûSHARESûATû53 ûTHEû
MIDPOINTûOFû53
ûMARKETINGûRANGEûANDû
INCREASEûFROMûMûSHARES
4HEûDEALûWASûMARKETEDûWITHûUPûTOû
US$20m of insider support but the
UNDERWRITERSûCLEARLYûFOUNDûENOUGHûBUYERS
!QUESTIVEûRANûUPûûTOûAûHIGHûOFû
53ûBEFOREûREVERSINGûCOURSEûINûTHEû
AFTERNOONûTOûAû53ûlNISH ûUPûûBUTû
BELOWûTHEû53û67!0
5NLIKEûMOSTûBIOTECHû)0/S ûTHEûPUBLICû
VALUATIONûISûUNDERPINNEDûBYûREVENUES
!QUESTIVEûTOOKûINû53MûOFûREVENUEûINû
THEûlRSTûQUARTERûFROMûITSûPARTNERSHIPSûWITHû
)DIVIORûANDû-IDATECHûONûSUBLINGUALû
FORMULATIONSûOFûTHEIRû&$!
APPROVEDûDRUGSû)Tû
also has its own proprietary pipeline of
drugs that are in various stages of clinical
DEVELOPMENT
4HEûLEADûDRUG ûCALLEDû3YMPAZAN ûISûANûORALû
SOLUBLEûlLMûVERSIONûOFûTHEûANTI
SEIZUREûDRUGû
CLOBAZAMû!QUESTIVEûSUBMITTEDûAûNEWûDRUGû
APPLICATIONûFORû3YMPAZANûLASTû/CTOBERûANDû
THEû&$!ûHASûUNTILû!UGUSTûûTOûRULEûONûTHEû
DRUGSûAPPROVALûORûTURNûITûDOWNLIQUIDIA FUNDS PIVOTAL TRIALLIQUIDIA THERAPEUTICSûRAISEDû53MûONû
7EDNESDAYûINûTHEûTHûBIOTECHû)0/ûTHISû
YEAR ûACCORDINGûTOû)&2ûDATA
Jefferies and CowenûPRICEDûMûSHARESûATû
53 ûMIDPOINTûTOûTHEû53nûRANGEûANDûAûûSTEP
UPûFROMûTHEû53û
equivalent price from a Series D round that
PRICEDûINû&EBRUARY
0ROCEEDS ûWHENûCOMBINEDûWITHû53Mû
from the Series D, provide full funding for an
ONGOINGû0HASEû)))ûTRIALûOFûITSûNEWûTREATMENTûFORû
PULMONARYûARTERIALûHYPERTENSION
4HEû)0/ûWASûBACKEDûWITHûUPûTOû53MûOFû
INSIDERûSUPPORT
,IQUIDIAûOPENEDûATû53ûFORûANû
IMMEDIATEûûRETURNûFORûNEWûINVESTORSû4HEû
STOCKûTRADEDûDOWNûTOû53ûATûTHEûCLOSE
,IQUIDIASûLEADûDRUGûISûAûPOTENTIALûCOMPETITORû
to United Therapeutics drug Tyvaso, which
GENERATEDû53MûINûSALESûLASTûYEARûASûAû
TREATMENTûFORûPULMONARYûARTERIALûHYPERTENSION
The drug is a dry powder formulation of
the active ingredient in Tyvaso that uses an
inhaler to get the drug deep into the
PATIENTSûLUNGSû0ROCEEDSûGIVEû,IQUIDIAû
53MûOFûCASH ûWHICHûISûENOUGHûTOû
COMPLETEûANûONGOINGû0HASEû)))ûTRIALûBYûMID
ECM DEALS: WEEK ENDING 27/7/2018
Stock Country Date Amount Price Deal type Bookrunner(s)
Evolution Mining Australia 16/07/18 A$257m A$2.79 Follow-on (Secondary) Citigroup, JP Morgan
Stella Jones Canada 24/07/18 C$343.6m C$40.63 Accelerated bookbuild (Secondary) TD Securities
Aurora Mobile Cayman Islands 25/07/18 US$76.5m US$8.50 IPO (Primary, Secondary) Goldman Sachs, Credit Suisse, Deutsche Bank
Pinduoduo Cayman Islands 25/07/ 18 US$1.63bn US$19.00 IPO (Primary) Credit Suisse, Goldman Sachs, CICC
Mall Plaza Chile 26/07/18 US$533.5m US$2.22 IPO (Secondary) JP Morgan, Morgan Stanley
Pinduoduo China 26/07/18 US$1.63bn US$19 IPO (Primary) CICC, Credit Suisse, China Renaissance, GS
Ascletis Pharma China 26/07/18 HK$3.1bn HK$14 IPO (Primary) China Merchants Securities, GS, Morgan Stanley
Aurora Mobile China 26/07/18 US$76.5m HK$8.5 IPO (Primary) Credit Suisse, Deutsche Bank, Goldman Sachs
Cango China 26/07/18 US$44m US$11 IPO (Primary) BAML, Goldman Sachs, Morgan Stanley
Navya France 23/07/18 €37.6m €7 IPO (Primary) Credit Suisse, Natixis/ODDO BHF
Consus Germany 23/07/18 €131m €7.20 Rights issue Deutsche Bank, UBS, Baader Bank
Greencoat Renewables Ireland 23/07/18 €111m €1.01 Follow-on (Primary) Davy, RBC
Invincible Investment Japan 25/07/18 US$374m ¥45,776 Follow-on (Primary) Mizuho Securities, Morgan Stanley, SMBC Nikko,
Citigroup, Normura
Opera Norway 27/07/18 US$115m US$12 IPO (Primary) CICC, Citigroup
DS Smith UK 24/07/18 £1bn 350p Rights issue Citigroup, Goldman Sachs, JP Morgan
Endava UK 26/07/18 US$128.0m US$20.00 IPO (Primary) MS, Citigroup, Credit Suisse, Deutsche Bank
Metro Bank UK 24/07/18 £302.84m £34.22 Accelerated bookbuild (Primary) RBC, KBW/Stifel Nicolaus Europe, Jefferies
Superdry UK 23/07/18 £71m £12.85 Accelerated bookbuild (Secondary) UBS
Aquestive Therapeutics US 24/07/18 US$67.5m US$15.00 IPO (Primary) BMO Capital Markets, RBC Capital Markets
Berry Petroleum US 25/07/18 US$182.6m US$14.00 IPO (Primary, Secondary) Goldman Sachs, Wells Fargo, BMO Capital Markets
Bloom Energy US 24/07/18 US$270.0m US$15.00 IPO (Primary) JP Morgan, Morgan Stanley
Bluebird bio US 24/07/18 US$549.3m US$162.50 Follow-on (Primary) Goldman Sachs, BAML, JP Morgan, Cowen
Cadence Bancorporation US 24/07/18 US$355.3m US$28.40 Accelerated bookbuild (Secondary) Goldman Sachs
Catalent US 24/07/18 US$400.0m US$40.24 Follow-on (Primary) JP Morgan , MS, RBC CM, BAML, Wells Fargo
Focus Financial Partners US 25/07/18 US$534.6m US$33.00 IPO (Primary) Goldman Sachs, BAML, KKR
Liquidia Technologies US 25 /07/18 US$50.0m US$11. 00 IPO (Primary) Jefferies, Cowen
Merit Medical Systems US 25/07/18 US$189.0m US$54. 00 Follow-on (Primary) Wells Fargo, Piper Jaffray
Nabriva Therapeutics US 26/07/18 US$50.0m US$2.75 Follow-on (Primary) Morgan Stanley
National Vision US 25/07/18 US$572.4m US$39.75 Follow-on (Secondary) BAML, Citigroup, Goldman Sachs, Jefferies, KKR
Noodles & Co US 26/07/18 US$85.0m US$10.00 Follow-on (Primary, Secondary) Jefferies, Citigroup, RBC Capital Markets
Reata Pharmaceuticals US 24/07/18 US$216.0m US$72.00 Follow-on (Primary) Jefferies, Leerink Partners, Stifel, Cantor Fitzgerald
Redwood Trust US 23/07/18 US$103.3m US$16.50 Accelerated follow-on (Primary) JP Morgan, Wells Fargo, GS, Credit Suisse
State Street US 26/07/18 US$1.15bn US$86.93 Accelerated follow-on (Primary) Morgan Stanley
Teladoc US 23/07/18 US$352.6m US$67. 00 Accelerated follow-on (Primary, Secondary) Jefferies
Tenable Holdings US 25/07/18 US$250.7m US$23.00 IPO (Primary) MS, JP Morgan, Allen & Co, Deutsche Bank
Veracyte US 25/07/18 US$51.3m US$10.25 Follow-on (Primary) Leerink Partners, WM Blair
WilScot US 25/07/18 US$128.0m US$16.00 Follow-on (Primary) Barclays, DB, MS, BAML, Credit Suisse, ING